Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Pulmonary function tests, sputum induction, and bronchial provocation tests: diagnostic tools in the challenge of distinguishing asthma and COPD phenotypes in clinical practice

Authors Efrossini Dima, Nikoletta Rovina, Christina Gerassimou, et al.

Published 2 September 2010 Volume 2010:5 Pages 287—296

DOI https://doi.org/10.2147/COPD.S9055

Review by Single-blind

Peer reviewer comments 3

Efrossini Dima1,2*, Nikoletta Rovina1,2*, Christina Gerassimou2, Charis Roussos1,2,3, Christina Gratziou2,3

1“Sotiria” Hospital for Diseases of the Chest, Department of Respiratory Medicine, University of Athens, Medical School, Athens, Greece; 2“M. Simos” Laboratories, Department of Critical Care and Pulmonary Services, Evangelismos Hospital, University of Athens, Athens, Greece; 3Asthma and Allergy Center, Evgenidion Hospital, Pulmonary and Critical Care Department, Medical School, University of Athens, Athens, Greece; *These authors contributed equally to this work

Background: Despite a number of important differences in the pathogenesis, course, and prognosis, asthma and chronic obstructive pulmonary disease (COPD) have many features in common. Furthermore, smoking induces considerable overlap in pathogenesis and clinical features between these conditions. This study aimed to reveal what inflammatory patterns prevail in clinically established diagnosis groups, including overlap phenotypes of asthma and COPD, and to evaluate the correlation with airway reversibility and hyperreactivity in these overlapping conditions.

Methods:
A total of 110 patients (17 healthy subjects; 16 “healthy” smokers; 46 asthma patients: 24 smokers and 22 non-smokers; and 31 COPD patients: 10 COPD patients with reversibility and 21 without) participated in the study. Induced sputum, reversibility testing, methacholine and adenosine 5’monophosphate (AMP) provocation challenges, and skin prick testing were performed. Airways inflammation was assessed by differential cell counts, and cytokines (interleukin-8 [IL-8] and tumor necrosis factor-alpha [TNF-α]) were measured in induced sputum by enzyme-linked immunosorbent assay (ELISA).

Results:
COPD patients with reversibility had increased sputum neutrophils, IL-8, and TNF-α levels compared to smoking asthmatics. No difference was found in inflammatory cells and cytokines between COPD subgroups. Sputum neutrophilia was inversely correlated with the change in forced expiratory volume in one second (ΔFEV1) in smoking asthmatic patients
(r = -0.563, P = 0.036). No correlation was found between airway hyperresponsiveness (AHR), either with methacholine or AMP, and inflammation in asthmatic patients, regardless of smoking. Reversibility was not correlated with inflammation in COPD patients. However, the response to AMP challenge was correlated with sputum neutrophils (r = 0.844, P = 0.001).

Conclusion:
Although overlaps exist in the disease characteristics of asthma and COPD, the combination of lung function testing, sputum induction, and AHR reveals information that facilitates the distinction between these diseases, allowing clinicians to better tailor their therapy.

Keywords: asthma, COPD, smoking, lung function, airway hyperresponsiveness

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease

Heike Rau-Berger, Harald Mitfessel, Thomas Glaab

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:367-373

Published Date: 10 October 2010

Budesonide/formoterol combination in COPD: a US perspective

Amir Sharafkhaneh, Amarbir S Mattewal, Vinu M Abraham, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:357-366

Published Date: 4 October 2010

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone

Beatrix Balint, Henrik Watz, Carolynn Amos, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:311-318

Published Date: 6 September 2010

Misdiagnosis of patients receiving inhaled therapies in primary care

José Luis Izquierdo, Antonio Martín, Pilar de Lucas, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:241-249

Published Date: 14 July 2010

Tumor necrosis factor-α serum levels in healthy smokers and nonsmokers

Florin Petrescu, Sebastian Cosmin Voican, Isabela Silosi

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:217-222

Published Date: 7 July 2010

Rhinosinusitis in COPD: symptoms, mucosal changes, nasal lavage cells and eicosanoids

Violetta M Piotrowska, Wojciech J Piotrowski, Zofia Kurmanowska, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:107-117

Published Date: 20 April 2010

Potential role of stem cells in management of COPD

Tillie L Hackett, Darryl A Knight, Don D Sin

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:81-88

Published Date: 26 March 2010